NeRRe Therapeutics

Founded in 2012, NeRRe Therapeutics Ltd. is dedicated to developing therapeutic solutions for cough hypersensitivity disorders.NeRRe Therapeutics specializes in the development of orvepitant, a neurokinin (NK)-1 receptor antagonist designed as a first-in-class, once-daily oral treatment targeting cough hypersensitivity disorders. The primary indication for orvepitant is chronic cough associated with idiopathic pulmonary fibrosis (IPF), a serious lung condition characterized by a persistent and often disabling cough that is resistant to existing medical therapies. NeRRe aims to address the unmet need in managing cough related to terminal diseases, particularly since IPF is recognized as an orphan disease in Europe and the USA.NeRRe Therapeutics has structured its business model around partnerships and collaborations, which are essential for advancing its clinical asset, orvepitant. Revenue generation is expected through licensing agreements with larger pharmaceutical companies and milestone payments linked to the success of clinical trials. Given the company's focus on a niche market, transactions may involve collaborations with healthcare providers managing chronic cough conditions, facilitating access to their treatment offerings. The company is focused on launching this innovative product while also exploring opportunities for expansion into new geographical markets, particularly in Europe and the United States, by the end of 2023. These initiatives will be critical in establishing NeRRe's presence in the market and addressing patient needs in cough management.

1. Series B

   Jun 25, 2021

   Amount

   $28M

   Investors

   Locked

2. Series B

   Jan 5, 2017

   Amount

   $28M

   Investors

   Locked

3. Series A

   Dec 19, 2012

   Amount

   $19M

   Investors

   Locked